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Abstract
Background: To compare the prescription modalities of general practitioners (GPs) and rheumatologists (RHs) for
symptomatic knee osteoarthritis (OA) and to determine correlates with prescription of low-dose NSAIDs.
Methods: This observational, prospective, national survey was carried out among a national representative sample
of GPs (n = 808) and RHs (n = 134). Each physician completed a medical questionnaire for the 2 most recent
patients fulfilling the ACR criteria for knee OA.
Results: GPs and RHs included 1,570 and 251 patients, respectively. Mean pain level of the knee (on a VAS, 0-100
mm) was greater for GP patients than for RH patients (49.8 ± 16.3 vs. 46.2 ± 17.1 mm, respectively; p < 0.01). As
compared with patients of RHs, those of GPs more frequently had another joint affected by OA: 71.2% vs. 63.7% (p
< 0.0001) and more often had hypertension and diabetes mellitus (p < 0.05).
As compared with RHs, GPs more frequently prescribed low-dose NSAIDs (p < 0.0001), oral NSAIDs (p < 0.05), and
topical NSAIDs (p < 0.0001) but less frequently symptomatic slow-acting drugs for OA (p < 0.01). Moreover, GPs
more frequently recommended rehabilitation (p < 0.01) and loss of weight (p < 0.0001). Logistic regression analysis
revealed an association of low-dose NSAIDs prescription and prescription by GPs, prescription of topical NSAIDs, no
prescription of oral NSAIDs or coxibs and no intra-articular injection of steroids.
Conclusions: This study identified speciality-related variability in some aspects of the management of knee OA.
The clinical profile of patients with knee OA differed between GPs and RHs.
Background
Osteoarthritis (OA) is the most prevalent joint disease
worldwide and a leading cause of chronic disability [1].
The prevalence of symptomatic knee OA has been
recently estimated to be 9% in the general population.
This estimate was computed with a Kellgren-Lawrence
score of ≥1u s e dt od e f i n eO A[ 2 ] .F r a n c eh a sa b o u t
40-fold more general practitioners (GPs; n = 101,667
in 2009) than rheumatologists (RHs; n = 2,625 in
2007) and thus, most symptomatic knee OA is mana-
ged by GPs.
Several recommendations have been published for the
treatment of knee OA, including non pharmacological
and pharmacological treatments, for both GPs and RHs
[3-5]. Use of these treatments may differ among GPs
and RHs, but few studies [6] have investigated the pre-
scription patterns of these two types of physicians for
the treatment of knee OA.
Because the prevalence of knee OA increases with age,
the safety of prescribed drugs deserves special consid-
eration, and the benefits and risks of prescribing non-
steroidal anti-inflammatory drugs (NSAIDs) must be
cautiously evaluated for each patient. Indeed, serious
side effects occur with the long-term use of NSAIDs by
elderly people with OA. The drugs can cause severe gas-
trointestinal complications, such as bleeding or perfora-
tion [7]. Several studies and meta-analyses have also
suggested an association of increased cardiovascular risk
and the use of traditional NSAIDs and coxibs [8,9].
Because of the dose-dependent elevation in cardiovascu-
lar and gastrointestinal risks [7,9], NSAIDs should be
used at the lowest effective dose for the shortest possible
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ibuprofen at up to 1200 mg or naproxen at up to 500
mg, may be associated with decreased cardiovascular
risk [9] and may be an interesting alternative to alleviate
pain in patients with OA. Indeed ibuprofen (400 mg
3 times daily) has been shown to be more effective than
acetaminophen (1000 mg 3 times daily) in reducing pain
and improving function in patients with knee or hip OA
[10].
We designed this national observational prospective
study to compare the prescription patterns of GPs and
RHs for patients with knee OA, with a special emphasis
on low-dose NSAIDs prescriptions.
We found that there is speciality-related variability in
some aspects of the management of knee OA and that
the clinical profile of patients with knee OA differed
between GPs and RHs.
Methods
Design
The study took the form of a cross-sectional survey by
questionnaires completed by GPs and RHs working full-
or part-time in different areas of France. This study was
conducted in accordance with the recommendations of
the Helsinki declaration. Ethical approval was not
required for this study, in accordance with national
guidelines.
Selection of physicians
GPs were randomly selected from the CEGEDIM regis-
try and RHs from the French Society of Rheumatology
registry. In total, 7,451 GPs and 1,777 RHs in private
practice were asked to participate; 1,194 GPs (16.0%)
and 225 RHs (12.7%) agreed and were sent question-
naires in May 2008. Finally, 808 GPs (67.6%) and 134
RHs (59.5%) recruited patients. This rate of participation
was expected and is usual for this kind of survey. The
demographics of these GPs and RHs did not signifi-
cantly differ from those of GPs and RHs in France in
general in terms of sex, age and number of years of
practice.
Patients
Participating GPs and RHs were asked to record data for
2 consecutive patients presenting symptomatic knee OA
according to the American College of Rheumatology cri-
teria [11]. Eligible patients with knee OA were ≥ 18
years old and did not have another condition that might
have interfered with the assessment of knee OA.
Questionnaire
After a clinical examination, physicians were asked to
complete a questionnaire covering the clinical character-
istics of OA, co-morbidities, current medications and
the different treatments prescribed for knee OA at the
end of the consultation. In France, low-dose NSAIDs
are sold over the counter and are ibuprofen (up to 1200
mg), ketoprofen (up to 75 mg/j) and naproxen (up to
660 mg/j). Additionally, available SYSADOA are avo-
cado/soybean unsaponifiable, chondroitin, glucosamine
and diacerein. The questionnaire was pragmatic and did
not provide the definition of the recorded co-morbidities
(hypertension, diabetes mellitus, peptic ulcer, cardiovas-
cular risk, history of cancer, anxiety, depression) to
avoid any bias in the prescription. Pain intensity was
assessed by a 100-mm visual analog scale (VAS). The
patients were also asked to report the presence or
absence of daily disability due to knee OA (yes/no) and
the presence or absence of pain at night (yes/no).
A pilot study included a group of 2 GPs and 2 RHs, as
well as a group of 4 clinical and non-clinical researchers
experienced in this type of survey, to test the question-
naire for comprehensibility and relevance.
Statistical analysis
Data are reported as mean ± standard deviation (SD) or
percentages. Comparisons between the data for GPs and
RHs involved the chi-square test or t test, as appropri-
ate. Multiple regression analysis was used to assess the
independent association of the prescription of low-dose
NSAIDs and other variables. Because the study was
exploratory, the sample size was calculated to provide a
satisfying precision in the worst situation for ordinal
data (rate of 50%). With an alpha risk of 5% and an
expected precision of 2.5%, the number of patients
needed was 1,536 and therefore 768 practitioners (who
would each recruit 2 patients). Because the expected
rate of practitioners actively recruiting patients among
those giving their consent to participate was 55%, we
invited 1,400 physicians (1,200 GPs and 200 RHs) to
participate. A P value < 0.05 was considered statistically
significant. All analyses involved use of SAS v9.2 (SAS
Inst., Cary, NC).
Results
Demographic characteristics of GPs and RHs
The 808 GPs and 134 RHs not differ in age (52.2 ± 6.8
vs. 52.7 ± 7.5 years) (Table 1). However, GPs were more
frequently male (89.4% vs. 67.2%; p < 0.0001), more
often practiced in rural areas (55.0% vs. 19.4%; p <
0.0001) and saw fewer patients with knee OA per week
than did RHs (11.1 ± 8.6 vs. 16.7 ± 8.5; p < 0.0001).
Demographic characteristics of patients with knee OA
GPs and RHs included 1,570 and 251 patients with knee
OA, respectively (Table 2). As compared with patients
of RHs, those of GPs had longer duration of OA (7.8 ±
5.6 vs. 6.8 ± 5.4 years; p < 0.01), more often experienced
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19.0 mm; p < 0.0001), and more frequently reported
pain at night (49.9% vs. 29.7%; p < 0.0001) and daily dis-
ability due to knee OA (90.6% vs. 84.3%; p < 0.01). As
compared with RH patients, GP patients more often had
another joint (hand or hip) affected by OA: 71.2% vs.
63.7% (p < 0.0001). The presence of one or more patho-
logical conditions was detected in 94.1% of patients. The
most frequent severe comorbidities were hypertension
(57.3%), diabetes mellitus (16.1%) and peptic ulcer
(12.7%). The 2 groups of patients differed in relative fre-
quencies of comorbid conditions (Table 3): hypertension
and diabetes mellitus were more frequent in GP patients
(p < 0.05 for both).
Prescription modalities of GPs and RHs
A high proportion of patients (80.8%) were receiving a
mean of 3.6 ± 2.2 medications for another condition,
and 4.5% were receiving oral anticoagulants. GPs and
RHs prescribed drugs for 89.0% and 83.3% of their
patients, respectively (p < 0.0001) (Table 4). GPs more
frequently than RHs prescribed low-dose NSAIDs
(15.1% vs. 5.2%; p < 0.0001), oral NSAIDs (35.0% vs.
25.5%; p < 0.05) and topical NSAIDs (31.1% vs. 15.9%;
p < 0.0001). By contrast, RHs more frequently
prescribed symptomatic slow-acting drugs for OA
(SYSADOAs) (45.0% vs. 39.1%; p < 0.01) and gave more
intra-articular injections of corticosteroids or hyaluronan
(Table 5). GPs more frequently recommended physical
therapy (p < 0.0001) and weight loss for obese patients
(p < 0.0001) (Table 4).
Correlates with prescription of low-dose NSAIDs
Prescription of low-dose NSAIDs did not depend on the
presence of cardiovascular risk factors, in contrast to
prescription of classical NSAIDs (p < 0.001) and coxibs
(p < 0.05) (Table 6). On logistic regression analysis, pre-
scription of low-dose NSAIDs was significantly asso-
ciated with prescription by GPs (odds ratio [OR] = 2.2
[95% confidence interval [CI] 1.1-4.5]), prescription of
topical NSAIDs (OR = 2.1 [95% CI 1.5-2.9]), no pre-
scription of NSAIDs or coxibs (OR = 36.2 [95% CI 15.8-
83.2] and OR = 16.0 [95% CI 4.8-52.7], respectively),
and no intra-articular injections (OR = 2.2 [95% CI
1.07-4.5]).
Discussion
This national observational prospective study was
designed to compare the prescription patterns of GPs
and RHs for their patients with knee OA, with a special
emphasis on the prescription of low-dose NSAIDs.
The results of our study are consistent with published
data showing that physicians in private practice in gen-
eral follow the international recommendations [3,5,12]
Table 1 Characteristics of general practitioners (GPs) and rheumatologists (RHs)
GPs
n = 808
RHs
n = 134
P value
Age, years 52.2 ± 6.8 52.7 ± 7.5 ns
Sex, % male 89.4 67.2 < 0.0001
Practice location: % metropolitan/rural 45.0/55.0 80.6/19.4 < 0.0001
Number of patients seen per week 141.1 ± 39.3 91.2 ± 30.0 < 0.0001
Number of patients with knee OA seen per week 11.1 ± 8.6 16.7 ± 8.5 < 0.0001
Values are mean ± SD or percentage. ns = not significant.
Table 2 Characteristics of patients with knee OA seen by general practitioners (GPs) and rheumatologists (RHs)
All patients
n = 1,821
GPs
n = 1,570
RHs
n = 251
P value
Age, years 67.3 ± 9.7 67.0 ± 9.7 69.8 ± 9.7 < 0.0001
Sex, % female 56.2 55.2 62.2 < 0.05
BMI, kg/m
2 28.9 ± 4.7 29.1 ± 4.6 28.0 ± 4.9 < 0.01
Duration of disease, years 7.7 ± 5.7 7.8 ± 5.6 6.8 ± 5.4 < 0.01
Pain (VAS, 0-100 mm)
On movement over the last 24 hr 61.6 ± 17.9 62.4 ± 17.6 57.3 ± 19.0 < 0.0001
At rest 32.7 ± 20.0 33.9 ± 20.5 25.3 ± 20.6 < 0.0001
Global pain 49.3 ± 16.4 49.8 ± 16.3 46.2 ± 17.1 < 0.01
Pain at night, % 47.1 49.9 29.7 < 0.0001
Daily disability, % 89.7 90.6 84.3 < 0.01
Presence of SF effusion, % 30.0 29.2 35.8 < 0.05
Values are mean ± SD or percentage. BMI = body mass index; VAS = visual analog scale; SF = synovial fluid.
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and RHs preferentially prescribed acetaminophen, and
conventional NSAIDs were more frequently prescribed
than were coxibs and low-dose NSAIDs. By contrast,
topical NSAIDs, which should be considered ahead of
oral NSAIDs according to the National Institute for
Health and Clinical Excellence guidelines [5], were less
frequently prescribed than were standard oral NSAIDs
[6,14].
Of interest, our study identified variability by medical
specialty in some aspects of the pharmacological treat-
ment of knee OA. Indeed, GPs more frequently pre-
scribed NSAIDs (conventional, low-dose and topical),
whereas RHs more often prescribed SYSADOAs and
more frequently gave intra-articular injections of ster-
oids and hyaluronic acid. This variability is similar to
what was found in the AMICA survey, which suggested
that the pharmacological management of knee OA dif-
fers between GPs and RHs [6,16]. Another explanation
could be the different clinical profile of patients seen by
GPs or RHs. Indeed, in our study, as compared with RH
patients, GP patients had longer duration of disease,
more frequently had another joint affected by OA and
the disease was more painful, as was previously noted in
other studies [6,17]. Although in France patients can
directly consult a specialist, these differences might be
due to patients’ more limited access to RHs, which leads
patients with painful disease to consult GPs more often.
Moreover, as shown in a previous British survey [17], a
mixture of physical, social and psychological factors
might predict visits to GPs, that may explain the differ-
ent clinical profile of patients with knee OA who con-
sulted GPs.
Our GPs and RHs did not differ in the prescription of
analgesics. Acetaminophen was prescribed for only 43%
of patients with chronic knee OA, which is far less that
the 95.8% recorded by Denoeud et al., who assessed the
pharmacological modalities prescribed by GPs as first-
line treatment for knee OA [13]. This relatively low use
of acetaminophen for chronic knee OA might be due to
Table 3 Co-morbidities in patients with knee OA seen by
general practitioners (GPs) and rheumatologists (RHs)
All patients
n = 1,821
GPs
n = 1,570
RHs
n = 251
P value
Hypertension 57.3 58.3 51.0 < 0.05
Diabetes mellitus 16.1 16.9 11.6 < 0.05
Peptic ulcer 12.7 11.9 17.5 < 0.05
Cardiovascular risk 27.5 28.2 23.5 ns
History of cancer 5.2 5.2 5.2 ns
Anxiety 21.8 22.9 14.7 < 0.01
Depression 12.2 12.7 8.8 ns
Values are percentages. ns = not significant
Table 4 Frequency of non pharmacological and oral
pharmacological treatments prescribed during the
consultation for knee OA for general practitioners (GPs)
and rheumatologists (RHs)
All
patients
n = 1,821
GPs
n=
1,570
RHs
n=
251
P
value
Pharmacological treatments
Acetaminophen 43.4 44.0 39.8 ns
Weak opioid analgesics 30.5 30.9 28.3 ns
Strong opioid analgesics 1.9 2.0 1.2 ns
Low-dose NSAIDs 13.3 15.1 5.2 <
0.0001
Oral NSAIDs 33.7 35.0 25.5 < 0.05
Coxibs 8.5 8.9 6.4 ns
Topical NSAIDs 29.0 31.1 15.9 <
0.0001
Proton pump inhibitor 25.9 26.9 19.5 < 0.05
Symptomatic slow-acting
drugs
39.9 39.1 45.0 < 0.01
Homeopathy 1.8 2.1 0.4 ns
Phytotherapy 2.9 2.7 4.4 ns
Non pharmacological
treatments
Weight loss (if obese) 63.4 65.4 51.4 <
0.0001
Information and education 54.6 52.3 68.9 <
0.0001
Exercise 35.7 33.9 47.4 <
0.0001
Physical therapy 21.1 33.8 21.9 < 0.001
Values are percentages. NSAIDs = nonsteroidal anti-inflammatory drugs. ns =
not significant
Table 5 Frequency of local treatments performed during
the consultation for knee OA by general practitioners
(GPs) and rheumatologists (RHs)
All patients
n = 1,821
GPs
n = 1,570
RHs
n = 251
P value
Arthrocentesis alone 5.8 3.9 17.9 < 0.0001
Corticosteroid injection 10.8 7.6 31.5 < 0.0001
Hyaluronan injection 8.5 2.5 46.2 < 0.0001
Values are percentages.
Table 6 Frequency of low-dose NSAIDS, NSAIDS or coxib
prescriptions according to the presence or absence of
cardiovascular risk in patients with knee OA
Absence of CV
risk
Presence of CV
risk
P
value
Low-dose NSAIDs (n =
250)
13.2 15.2 ns
NSAIDs (n = 613) 36.7 25.8 <
0.0001
Coxibs (n = 155) 9.5 6.0 < 0.05
Values are percentages. CV = cardiovascular; NSAIDs = non steroidal anti-
inflammatory drugs. ns = not significant.
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alleviate pain [18].
GPs and RHs did not often recommend nonpharma-
cological modalities such as information, physical ther-
apy, exercise or weight loss (for obese people). For
example, weight reduction, which has been showed to
be effective in alleviating pain in patients with knee OA
[19], was recommended by only about half of the RHs
and 65% of the GPs. These figures, which are close to
those obtained from a recent survey of GPs [14], high-
light the need to improve the dissemination of recom-
mendations for nonpharmacological treatment of
OA [20].
Another interesting finding is the high proportion of
patients with knee OA who had hypertension (57.3%) or
another cardiovascular risk factor (27.5%). These results
are in accordance with results of a large survey showing
that 40% of patients with OA have hypertension as com-
pared with 25% in the general population [21]. This
point is of importance given the known increased cardi-
ovascular risk associated with the use of traditional
NSAIDs and coxibs, in particular for patients with
established cardiovascular conditions. Of note, hyperten-
sion and diabetes mellitus were more frequent in GP
patients, who were more often prescribed NSAIDs to
alleviate OA pain. Cyclooxygenase inhibition causes
adverse effects, in particular blood pressure elevation,
mainly by impairing the systemic and renal vasodilata-
tory benefits of prostacyclin [22]. GPs and RHs seem to
be aware of this key notion, and it affects their prescrip-
tion practice because we found that NSAIDs and coxibs
were prescribed less for patients with a known cardio-
vascular risk.
A recent large-scale study has also demonstrated a
dose-dependant relation between the use of conven-
tional NSAIDs or coxibs and risk of death and myocar-
dial infarction in healthy individuals [9]. By contrast, use
of low-dose ibuprofen was associated with decreased
risk of cardiovascular events, which could be due to an
antithrombotic effect comparable to that of aspirin [9].
In our survey, as compared with the prescription of
classical NSAIDs and coxibs, that of low-dose NSAIDs
did not depend on the perceived presence of cardiovascu-
lar risk factors and was associated with prescription by
GPs, prescription of topical NSAIDs and no prescription
of NSAIDs or coxibs. Thus, these practitioners prescribe
low-dose NSAIDs as an alternative to conventional
NSAIDs or coxibs for patients with knee OA, regardless
of their cardiovascular profile.
Our study contains some limitations. Although the
response rate was high (67%), participants may not have
been representative of all GPs and RHs. Moreover, the
proportion of GPs was much higher than that of RHs,
for demographic reasons.
Conclusions
Our study found that GPs and RHs see a different clini-
cal profile of patients with knee OA. GP patients more
often exhibit severe conditions and more often have vas-
cular comorbidities. GPs and RHs show some variability
in their management of knee OA in that GPs more
frequently prescribe NSAIDs. Finally, low-dose NSAIDs,
a medication prescribed more often by GPs than RHs, is
used as an alternative to conventional NSAIDs or cox-
ibs, independent of the perceived presence of cardiovas-
cular risk factors.
Funding
This study was performed with the support of an inde-
pendent grant provided by Wyeth-Santé Familiale
France, which was not involved in the statistical analysis.
Acknowledgements
The authors thank all the physicians and all people with knee OA who took
part in the study.
Author details
1Univ Paris Diderot, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de
Paris, Hôpital Lariboisière, Fédération de Rhumatologie, 75010, Paris, France.
2Service de Rhumatologie, Centre hospitalier Sud Francilien, Corbeil-
Essonnes, France.
3Service de Rhumatologie, Hôpital Dupuytren, Limoges,
France.
4Service de Biométrie, Cenbiotech et Ceren, Dijon, France.
5Nukleus,
Département Etudes Cliniques, Paris, France.
6Université Paris 12, UFR
médicale, Assistance Publique-Hôpitaux de Paris, Service de Rhumatologie,
Hôpital Henri Mondor, Créteil, France.
Authors’ contributions
PR has written the manuscript. All authors (PR, PH, PB, PC, VB, MM) have
made substantial contributions to conception and design, analysis and
interpretation of data. PC and MM have performed the statistical analysis.
MM has helped to draft the paper. All authors read and approved the final
manuscript.
Competing interests
All authors have received fees (less than 1000 euros) from Wyeth-Santé
familiale (France) as members of the scientific committee of this study
named “Apaise”.
Received: 10 November 2010 Accepted: 12 April 2011
Published: 12 April 2011
References
1. Lohmander LS, Roos EM: Clinical update: treating osteoarthritis. Lancet
2007, 370:2082-2084.
2. Roux CH, Saraux A, Mazieres B, Pouchot J, Morvan J, Fautrel B, Testa J,
Fardellone P, Rat AC, Coste J, Guillemin F, Euller-Ziegler L: Screening for
hip and knee osteoarthritis in the general population: predictive value
of a questionnaire and prevalence estimates. Ann Rheum Dis 2008,
67:1406-1411.
3. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P,
Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P,
Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K,
Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-
Gorska I, Dougados M: EULAR Recommendations 2003: an evidence
based approach to the management of knee osteoarthritis: Report of a
Task Force of the Standing Committee for International Clinical Studies
Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
4. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N,
Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M,
Richette et al. BMC Musculoskeletal Disorders 2011, 12:72
http://www.biomedcentral.com/1471-2474/12/72
Page 5 of 6Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI
recommendations for the management of hip and knee osteoarthritis,
Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis
Cartilage 2008, 16:137-162.
5. Conaghan PG, Dickson J, Grant RL: Care and management of
osteoarthritis in adults: summary of NICE guidance. Bmj 2008,
336:502-503.
6. Scarpa R, Sarzi-Puttini P, Cimmino MA, Caporali R, Parazzini F, Zaninelli A,
Canesi B: Analysis of pharmacologic and nonpharmacologic prescription
patterns of general practitioners and specialists in the AMICA study.
Semin Arthritis Rheum 2005, 35:24-30.
7. Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA:
Variability among nonsteroidal antiinflammatory drugs in risk of upper
gastrointestinal bleeding. Arthritis Rheum 2010, 62:1592-1601.
8. McGettigan P, Henry D: Cardiovascular risk and inhibition of
cyclooxygenase: a systematic review of the observational studies of
selective and nonselective inhibitors of cyclooxygenase 2. Jama 2006,
296:1633-1644.
9. Fosbol EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK,
Sorensen R, Rasmussen JN, Andersen SS, Abildstrom SZ, Traerup J,
Poulsen HE, Rasmussen S, Kober L, Torp-Pedersen C: Risk of myocardial
infarction and death associated with the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) among healthy individuals: a nationwide
cohort study. Clin Pharmacol Ther 2009, 85:190-197.
10. Boureau F, Schneid H, Zeghari N, Wall R, Bourgeois P: The IPSO study:
ibuprofen, paracetamol study in osteoarthritis. A randomised
comparative clinical study comparing the efficacy and safety of
ibuprofen and paracetamol analgesic treatment of osteoarthritis of the
knee or hip. Ann Rheum Dis 2004, 63:1028-1034.
11. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W,
Cooke TD, Greenwald R, Hochberg M, et al: Development of criteria for
the classification and reporting of osteoarthritis. Classification of
osteoarthritis of the knee. Diagnostic and Therapeutic Criteria
Committee of the American Rheumatism Association. Arthritis Rheum
1986, 29:1039-1049.
12. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK,
Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M,
Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI
recommendations for the management of hip and knee osteoarthritis:
part III: Changes in evidence following systematic cumulative update of
research published through January 2009. Osteoarthritis Cartilage 2010,
18:476-499.
13. Denoeud L, Mazieres B, Payen-Champenois C, Ravaud P: First line
treatment of knee osteoarthritis in outpatients in France: adherence to
the EULAR 2000 recommendations and factors influencing adherence.
Ann Rheum Dis 2005, 64:70-74.
14. Conrozier T, Marre JP, Payen-Champenois C, Vignon E: National survey on
the non-pharmacological modalities prescribed by French general
practitioners in the treatment of lower limb (knee and hip)
osteoarthritis. Adherence to the EULAR recommendations and factors
influencing adherence. Clin Exp Rheumatol 2008, 26:793-798.
15. Chevalier X, Marre JP, de Butler J, Hercek A: Questionnaire survey of
management and prescription of general practitioners in knee
osteoarthritis: a comparison with 2000 EULAR recommendations. Clin Exp
Rheumatol 2004, 22:205-212.
16. Chard J, Dickson J, Tallon D, Dieppe P: A comparison of the views of
rheumatologists, general practitioners and patients on the treatment of
osteoarthritis. Rheumatology (Oxford) 2002, 41:1208-1210.
17. Mitchell HL, Carr AJ, Scott DL: The management of knee pain in primary
care: factors associated with consulting the GP and referrals to
secondary care. Rheumatology (Oxford) 2006, 45:771-776.
18. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G:
Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006, , 1:
CD004257.
19. Christensen R, Bartels EM, Astrup A, Bliddal H: Effect of weight reduction in
obese patients diagnosed with knee osteoarthritis: a systematic review
and meta-analysis. Ann Rheum Dis 2007, 66:433-439.
20. Roberts C, Adebajo AO, Long S: Improving the quality of care of
musculoskeletal conditions in primary care. Rheumatology (Oxford) 2002,
41:503-508.
21. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW: Prevalence of
cardiovascular disease risk factors among US adults with self-reported
osteoarthritis: data from the Third National Health and Nutrition
Examination Survey. Am J Manag Care 2002, 8:S383-391.
22. Moore RA, Derry S, McQuay HJ: Cyclo-oxygenase-2 selective inhibitors
and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal
and cardiovascular risk. BMC Musculoskelet Disord 2007, 8:73.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/12/72/prepub
doi:10.1186/1471-2474-12-72
Cite this article as: Richette et al.: Comparison of general practitioners
and rheumatologists’ prescription patterns for patients with knee
osteoarthritis. BMC Musculoskeletal Disorders 2011 12:72.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Richette et al. BMC Musculoskeletal Disorders 2011, 12:72
http://www.biomedcentral.com/1471-2474/12/72
Page 6 of 6